Article
AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
Leukemia research - 1 May 2018
Kavanagh Simon, Heath Emily, Hurren Rose, Gronda Marcela, Barghout Samir H, Liyanage Sanduni U, Siriwardena Thirushi P, Claudio Jaime, Zhang Tong, Sukhai Mahadeo, Stockley Tracy L, Kamel-Reid Suzanne, Rostom Amr, Lutynski Andrzej, Khalaf Dina, Rydlewski Anna, Chan Steven M, Gupta Vikas, Maze Dawn, Sibai Hassan, Schuh Andre C, Yee Karen, Minden Mark D, Schimmer Aaron D
Abstract excerpt
We evaluated outcomes of 100 patients with high risk AML treated with Ida-FLAG induction as first-line therapy. 72 achieved remission with one cycle; 19 did not. High risk cytogenetics and TP53 mutations were associated with failure to achieve remission. In those reaching remission, allogeneic bone marrow transplantation was associated with better relapse-free and overall survival. Those not achieving remission...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.